- Home
- GIGM vs EDSA Comparison
GIGM vs EDSA Comparison
Compare GIGM & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GIGM
- EDSA
- Stock Information
- Founded
- GIGM 1998
- EDSA 2015
- Country
- GIGM Taiwan
- EDSA Canada
- Employees
- GIGM N/A
- EDSA 16
- Industry
- GIGM Computer Software: Programming Data Processing
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- GIGM Technology
- EDSA Health Care
- Exchange
- GIGM Nasdaq
- EDSA Nasdaq
- Market Cap
- GIGM 16.1M
- EDSA 14.7M
- IPO Year
- GIGM 2000
- EDSA N/A
- Fundamental
- Price
- GIGM $1.43
- EDSA $2.39
- Analyst Decision
- GIGM
- EDSA Strong Buy
- Analyst Count
- GIGM 0
- EDSA 2
- Target Price
- GIGM N/A
- EDSA $13.00
- AVG Volume (30 Days)
- GIGM 5.7K
- EDSA 30.7K
- Earning Date
- GIGM 07-30-2025
- EDSA 08-08-2025
- Dividend Yield
- GIGM N/A
- EDSA N/A
- EPS Growth
- GIGM N/A
- EDSA N/A
- EPS
- GIGM N/A
- EDSA N/A
- Revenue
- GIGM $3,103,000.00
- EDSA N/A
- Revenue This Year
- GIGM N/A
- EDSA N/A
- Revenue Next Year
- GIGM N/A
- EDSA N/A
- P/E Ratio
- GIGM N/A
- EDSA N/A
- Revenue Growth
- GIGM N/A
- EDSA N/A
- 52 Week Low
- GIGM $1.27
- EDSA $1.55
- 52 Week High
- GIGM $1.80
- EDSA $5.59
- Technical
- Relative Strength Index (RSI)
- GIGM 48.05
- EDSA 73.15
- Support Level
- GIGM $1.40
- EDSA $1.89
- Resistance Level
- GIGM $1.49
- EDSA $2.23
- Average True Range (ATR)
- GIGM 0.06
- EDSA 0.11
- MACD
- GIGM -0.00
- EDSA 0.04
- Stochastic Oscillator
- GIGM 28.12
- EDSA 81.54
About GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.